Trials
3 active
4 in total · 4 in the EU
What this is
- How it works
- A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
- Tested for
- Transthyretin Amyloidosis (ATTR) With Cardiomyopathy (2 trials), Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
- Main trialPhase 3
- “This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in participants with ATTR amyloidosis with cardiomyopathy.”In the company’s words, NCT04153149 on ClinicalTrials.gov
- Other names
- ALN-TTRSC02 · AMVUTTRA
Other drugs for Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- NTLA-2001Intellia Therapeutics · Phase 3
- AcoramidisEidos Therapeutics, a BridgeBio company · Marketed (Phase 4 trial)
Coming up2
- 27 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Mar 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 8 May 2024 | HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | |
| Phase 3Recruiting | 27 Dec 2027 | TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy | |
| Phase 3Enrolling by invitation | 31 Mar 2028 | A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | |
| Phase 3Completed | 10 Nov 2020 | HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026